IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of ITZELER, et al.

Application No.: 10/642,970

Filed: August 18, 2003

Title:

Ø

INDOLE DERIVATIVES OR BENZIMIDAZOLE DERIVATIVES

FOR MODULATING IKB KINASE

Examiner:

Art Unit:

1754

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

(b)	This	This Information Disclosure Statement is filed after the period set forth in 37 C.F.R.						
	1.97	(b), but is believed to be filed before the mailing date of a final action under §1.113						
	or a notice of allowance under §1.311, whichever occurs first.							
	(1)	The undersigned attorney certifies that each item of information contained in this						
		Information Disclosure Statement was cited in a communication from a foreign						
		patent office in a counterpart foreign application not more than three months prior						
•		to the filing of this statement;						
	(2)	The undersigned attorney certifies that no item of information contained in this						
		Information Disclosure Statement was cited in a communication from a foreign						
		patent office in a counterpart foreign application or, to the knowledge of the						
		undersigned attorney after making reasonable inquiry, was known to any						
		individual designated in §1.56(c) more than three months prior to the filing of this						
		statement; or						
	(3)	This Information Disclosure Statement is accompanied by a transmittal letter in						
		which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is						
		authorized.						
		Respectfully submitted,						
		(Vila Arte Ca						
		Julie Anne Knight, Reg. No. 48,867						
	Attorney/Agent for Applicant .							

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3679
Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0063 US NP

Please type a plus sign (+) inside this box ->	/
--	---

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

1

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

1


Complete if Known					
Application Number	10/642,970				
Filing Date	08-18-2003				
First Named Inventor	RITZELER				
Group Art Unit	1754				
Examiner Name					
Attorney Docket Number	DEAV2002/0063 - US - NP				

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	U.S. Patent D	Nocument Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		2003/0119820		RITZELER, et al.	06-26-2003		
		6358978		RITZELER, et al.	03-19-2002		
_						0	
	-						
			- 1				

	FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.1	Foreign Patent Document Kind Code ⁵ Office ³ Number ⁴ (if known)				Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant	T6
		wo	94/12478	<u>`</u>		KEENAN, et al.	06-09-1994	Figures Appear	
		<u> </u>							
		_		-+		<u>-</u>	<u> </u>		\vdash
		_	<u> </u>						\vdash

Examiner	Date	
Signature	Considered	

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.